title: VOLUME 31: HTA'S EVOLUTION: FROM CONSUMER TO HONEST BROKER TO ENGAGED COLLABORATOR.
abstract: In this issue, Facey and colleagues have eloquently summarized the product of the February 2015 HTAi Policy Forum discussion-the need for health technology assessment (HTA) to shift from a historically reactive role in both evaluating current evidence and requesting additional evidence generation to a more proactive role engaging with stakeholders to ensure that evidence produced is appropriate for any given intervention at different stages of the clinical development program. This makes logical a priori sense, of course, as proactive and engaged discussion is always superior to reactive and potentially adversarial interaction.
authors.affiliation: Institute for Clinical and Economic Reviewdollendorf@icer-review.org.
authors.forename: Daniel A
authors.identifier: http://orcid.org/0000-0003-1978-2471
authors.initials: DA
authors.lastname: Ollendorf
mesh_terms: D004059:Diffusion of Innovation; D011050:Policy Making; D013673:Technology Assessment, Biomedical